Kaplan-Meier curve of progression-free survival (PFS) (a) and overall... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Breast Cancer Survival Rates: Prognosis by Age, Race & More
Peregrine Pharmaceuticals, Inc. Drug Doubles Lung Cancer Survival in Trial | BioSpace
Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis | Scientific Reports
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Overall survival and breast-cancer-specific survival curves according... | Download Scientific Diagram
The role of censoring on progression free survival: Oncologist discretion advised - ScienceDirect
Cancer - Our World in Data
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Figure 1 from Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | Semantic Scholar
Adjuvant chemotherapy improves overall survival in patients with stage IB non-small cell lung cancer
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing r
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
Prognostic factors in epithelial ovarian cancer: A population-based study | PLOS ONE
Oncotarget: Melatonin increases overall survi | EurekAlert!
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
